Lavoltidine
Lavoltidine Basic information
- Product Name:
- Lavoltidine
- Synonyms:
-
- 1-Methyl-5-[[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-1H-1,2,4-triazole-3-methanol
- 1H-1,2,4-Triazole-3-methanol, 1-methyl-5-((3-(3-(1-piperidinylmethyl)phenoxy)propyl)amino)-
- 86160-82-9 (Hemisuccinate[1:1])
- Lavoltidina
- Lavoltidina [inn-spanish]
- Lavoltidine [inn:ban]
- Lavoltidinum
- Lavoltidinum [inn-latin]
- CAS:
- 76956-02-0
- MF:
- C19H29N5O2
- MW:
- 359.471
- Mol File:
- 76956-02-0.mol
Lavoltidine Usage And Synthesis
Uses
Anti-ulcerative (histamine H2-receptor block er).
Definition
ChEBI: Loxtidine is a triazole that consists of 1,2,4-triazole bearing a methyl substituent at position 1, a hydroxymethyl substituent at position 3 and a {3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}amino group at position 5. A highly potent and selective H2-receptor antagonist. It has a role as a H2-receptor antagonist. It is a member of triazoles, a member of piperidines, an aromatic ether and a primary alcohol.
in vivo
Lavoltidine (Loxtidine; 0.5 g/L; orally (drinking water); changed weekly; for 3 months) shows partial suppression of both gastric acid secretion and progression to neoplasia. Lavoltidine inhibits gastric atrophy, hyperplasia, and dysplasia in H felis-infected INS-GAS mice[1].
Lavoltidine treatment for 6 months inhibits gastric tumors in H felis-infected INS-GAS mice[1].
| Animal Model: | Male hypergastrinemic mice (INS-GAS mice) infected with Helicobacter felis[1] |
| Dosage: | 0.5 g/L |
| Administration: | Orally (drinking water); changed weekly; for 3 months |
| Result: | Showed partial suppression of both gastric acid secretion and progression to neoplasia. |
IC 50
H2 Receptor
LavoltidineSupplier
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 18871490254
- linda@hubeijusheng.com
- Tel
- 13348960310
- 3003867561@qq.com
- Tel
- 010-60605840 15801484223;
- psaitong@jm-bio.com
- Tel
- 4008200310
- marketing@tsbiochem.com